Abstract
The objective of this study was to evaluate the different profiles of serum lipids resulting from the administration of selective estrogen receptor modulators (SERMs). Postmenopausal primary breast cancer patients (n=197) with node-negative, hormone receptor-positive who were treated at our department or in other related medical institutions from April 1997 through March 2001 were given adjuvant therapy. The adjuvant therapy included 1 year's administration of tamoxifen (TAM) 20 mg or toremifene (TOR) 40 mg. The profiles of serum lipids such as total cholesterol (TC), high-density lipoprotein cholesterol (HDL) and triglyceride (TG) were observed. After 1 year administration TC had significantly decreased (p < 0.001) both in the TAM group and the TOR group, but no significant difference was found between these groups (p=0.249). HDL had significantly decreased in the TAM group (p < 0.001), while it had significantly increased in the TOR group (p < 0.001), and a significant difference was found between the groups (p < 0.001). TG had significantly increased in the TAM group (p < 0.001) but significantly decreased in the TOR group (p < 0.001). The medication was switched in those who still had abnormal lipid metabolism and given to them for another year. After 1 year from the crossover TC and HDL had increased to the levels of before administration (p < 0.001) and TG had decreased in those (n=57) whose medication was switched from TAM to TOR. While TC had decreased and TG had increased in those (n=23) whose medication was switched from TOR to TAM (p < 0.001). The above findings have suggested that TOR provides better profiles of lipid metabolism than TAM.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Love RR, Wiebe DA, Feyzi JM, Newcom PA, Chappel RJ: Effects of tamoxifen on cardiovascular risk factors in postmenopausal woman after 5 years of treatment. J Natl Cancer Inst 86: 1534–1539, 1994
Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O: Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocr Metab 83: 1158–1162, 1998
Riggs LR, Hartmann LC: Selective estrogen-receptor modulators–mechanisms of action and application to clinical practice. New Engl J Med 348: 618–629, 2003
Saarto T, Blomqvist C, Ehnholm C, Taskinen M-R, Elomaa I: Antiaetherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of Tamoxifen and Toremifene on plasma lipid levels in post-menopausal woman with node-positive breast cancer. J Clin Oncol 14: 429–433, 1996
Joensuu H, Holli K, Oksanen H, Valavaara R: Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 63: 225–234, 2000
Japan Arthrosclerosis Society, Exploratory Committee of Guideline for Diagnosis of Hyperlipidemia: Guideline for Diagnosis of Hyperlipidemia I, diagnosis standards of adult hyperlipidemia, standards of applicable therapies, target values of therapies. Arthrosclerosis 25: 134, 1997
Roberts WC: Atherosclerotic risk factors. Are there ten or is there only one? Am J Cardiol 64: 552–554, 1989
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 339: 1349–1357, 1998
Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E: Effect of pravastatin on cardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial. Ann Intern Med 1 29: 681–689, 1998
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 62: 707–714, 1977
Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, Kagan A, Zukel WJ: HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 55: 767–772, 1977
Carlson LA, Bottiger LE, Ahfeldt PE: Risk factors for myocardial infarction in the Stockholm prospective study; A 14–years follow-up focusing on the role of plasma triglycerides and cholesterol. Acta Med Scand 206: 351–360, 1979
Carlson LA, Bottiger LE: Risk factors for ischemic heart disease in men and women; Results of the 19–years follow-up of the Stockholm prospective study. Acta Med Scand 218: 207–211, 1985
Castelli WP: The triglyceride issue: a view from Framingham. Am Heart J 112: 432–437, 1986
Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, Goldbourt U: Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registory. Circulation 100: 475–482, 1999
Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451–1467, 1998
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371–1388, 1998
Brun LD, Gaugne C, Rousseau C, Moorjani S, Lupien PJ: Severe lipemia induced by tamoxifen. Cancer 57: 2123–2126, 1987
Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G, Bertolini S, Rosso R: Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 52: 339–346, 1988
Kangas L, Nieminen AL, Blanco G, Gronroos M, Kallio S, Karjalainen A, Perila M, Sodervall M, Toivola R: A new triphenylethylene compound, FC-1157a: II. Antitumor effect. Cancer Chemoth Pharmacol 17: 109–113, 1986
Pyrhonen S, Ellmen J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, Hayes DF: Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 56: 133–143, 1999
Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E, Joensuu H: Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J Clin Oncol 18: 3487–3494, 2000
Pagani O, Gelber S, Simoncini E, Holmberg SB, Colleoni M, Crivellari D, Aebi S, Castiglion-Gertsch M, Gelber RD, Goldhirsch A: Randomized comparison of adjuvant toremifene (Tor) versus tamoxifen (Tam) foe postmenopausal women with node-positive (N+), estrogen receptor-positive (ER+) early stage breast cancer. Proc Am Soc Clin Oncol 22: 20, 2003
Salle E, Zaccheo T, Ornati G: Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36: 203–206, 1990
Harvey HA, Hajba A: Stroke incidence with toremifene is lower than with tamoxifen in breast cancer patients. Proc Am Soc Clin Oncol 22: 741, 2003
Ohni M, Mizukawa S, Nakajima K, Yamamoto M, Hata Y: Insulin resistance and hyperlipidemia in the elderly, Jpn J Geriatr 34: 379–388, 1997
Stiko-Rahm A, Wiman B, Hamsten A: Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endotherial cell is induced by very low density lipoprotein. Atheroscleosis 10: 1067–1073, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kusama, M., Kaise, H., Nakayama, S. et al. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations. Breast Cancer Res Treat 88, 9–16 (2004). https://doi.org/10.1007/s10549-004-5449-8
Issue Date:
DOI: https://doi.org/10.1007/s10549-004-5449-8